FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents a therapeutic agent used for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by a multifunction kinase inhibitor (MKI) therapy and containing a therapeutically effective amount of allopurinol or its pharmaceutically acceptable salt.
EFFECT: invention provides extending the range of products for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by the multifunction kinase inhibitor (MKI) therapy.
21 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING PALMAR-PLANTAR ERYTHRODYSESTHESIA | 2018 |
|
RU2722396C2 |
| APPLICATION OF ALLOPURINOL FOR TREATING PALMOPLANTAR ERYTHRODYSESTHESIA | 2007 |
|
RU2438673C2 |
| METHOD FOR PREVENTION OR TREATMENT OF SIDE EFFECT OF TUMOR THERAPY | 2019 |
|
RU2782033C2 |
| USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | 2014 |
|
RU2666219C2 |
| RET INHIBITOR FOR USE IN THE TREATMENT OF CANCER WITH RET ALTERATION | 2019 |
|
RU2800951C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| TREATING CANCER WITH COMBINATION OF RADIATION THERAPY, CERIUM OXIDE NANOPARTICLES AND CHEMOTHERAPEUTIC AGENT | 2015 |
|
RU2704811C2 |
| APILIMOD COMPOSITION AND METHODS OF USING IT IN TREATING MELANOMA | 2015 |
|
RU2731908C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
